EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Lixuan Qian, Jessica L Beers iD, Klarissa D Jackson iD, Zhu Zhou

Pharmaceutics · 01.04.2024 · 16 (4) · 484

DOI: 10.3390/pharmaceutics16040484 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 01.04.2024. Verfasst von Lixuan Qian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, York College, City University of New York, Jamaica, NY 11451, USA. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 249 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, NIGMS NIH HHS, NIH/NIGMS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cannabinoid use has surged in the past decade, with a growing interest in expanding cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) applications into special populations. Consequently, the increased use of CBD and THC raises the risk of drug–drug interactions (DDIs). Nevertheless, DDIs for cannabinoids, especially in special populations, remain inadequately investigated. While some clinical trials have explored DDIs between therapeutic drugs like antiepileptic drugs and CBD/THC, more potential interactions remain to be examined. This review summarizes the published studies on CBD and THC–drug interactions, outlines the mechanisms involved, discusses the physiological considerations in pharmacokinetics (PK) and DDI studies in special populations (including pregnant and lactating women, pediatrics, older adults, patients with hepatic or renal impairments, and others), and presents modeling approaches that can describe the DDIs associated with CBD and THC in special populations. The PK of CBD and THC in special populations remain poorly characterized, with limited studies investigating DDIs involving CBD/THC in these populations. Therefore, it is critical to evaluate potential DDIs between CBD/THC and medications that are commonly used in special populations. Modeling approaches can aid in understanding these interactions.

Schlagwörter

Stichwörter der Autor:innen

cannabidioldelta-9-tetrahydrocannabinoldrug–drug interactionspecial population

Autor:innen und Institutionen

  • Department of Chemistry, York College, City University of New York, Jamaica, NY 11451, USA.
  • Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

ORCID-Profile: Jessica L Beers, Klarissa D Jackson

Förderung

  • NIEHS NIH HHS
  • NIGMS NIH HHS
  • NIH/NIGMS

Zitieren

APA

Qian, L., Beers, J. L., Jackson, K. D., & Zhou, Z. (2024). CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions. Pharmaceutics, 16(4), 484. https://doi.org/10.3390/pharmaceutics16040484

Vancouver

Qian L, Beers JL, Jackson KD, Zhou Z. CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions. Pharmaceutics. 2024;16(4):484. doi:10.3390/pharmaceutics16040484

BibTeX
@article{Qian2024,
  author = {Qian, Lixuan and Beers, Jessica L and Jackson, Klarissa D and Zhou, Zhu},
  title = {CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {4},
  pages = {484},
  doi = {10.3390/pharmaceutics16040484}
}
Kostenlos starten →